Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions.

Drugs - 1 Jul 2026

Lau Eunice L Y, Sahib Noor Rashidha Binte Meera, Cangco Carina Ysha P, Tan Aaron C

Abstract excerpt

Epidermal growth factor receptor (EGFR) exon 20 insertions are the third most common EGFR mutation subtype in non-small cell lung cancer, occurring in up to ~4% of cases. Although the clinical profile overlaps with classical sensitizing EGFR mutations, most exon 20 insertions confer primary resistance to earlier generation epidermal growth factor receptor tyrosine kinase inhibitors, reflecting position- and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutagenesis, Insertional

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 42154197
DOI: 10.1007/s40265-026-02329-7
PMCID: PMC13290872

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions.PMID 42154197Read ↗

The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives.Semantic proximity Read ↗

Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the ArtSemantic proximity Read ↗

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutationsSemantic proximity Read ↗

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.Semantic proximity Read ↗

Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).Semantic proximity Read ↗

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidationSemantic proximity Read ↗

EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read ↗

Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients.Semantic proximity Read ↗

EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.Semantic proximity Read ↗

[The research status and development trend of EGFR gene exon 20 insertion mutant non-small cell lung cancer].Semantic proximity Read ↗

Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC.Semantic proximity Read ↗

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.